Establishment Labs (NASDAQ:ESTA) Shares Down 7.4% – Should You Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) dropped 7.4% during mid-day trading on Thursday . The company traded as low as $35.51 and last traded at $35.23. Approximately 176,473 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 416,768 shares. The stock had previously closed at $38.05.

Analyst Ratings Changes

Separately, Stephens reiterated an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Establishment Labs presently has an average rating of “Moderate Buy” and a consensus price target of $57.40.

Establishment Labs Price Performance

The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -14.36 and a beta of 0.95. The business’s 50-day simple moving average is $36.43 and its two-hundred day simple moving average is $41.09. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). The firm had revenue of $44.51 million for the quarter, compared to analyst estimates of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC grew its position in shares of Establishment Labs by 9,643.3% during the 3rd quarter. Barclays PLC now owns 31,471 shares of the company’s stock worth $1,362,000 after buying an additional 31,148 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Establishment Labs by 89.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock worth $1,789,000 after buying an additional 19,531 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Establishment Labs during the 4th quarter worth approximately $12,898,000. Vestal Point Capital LP acquired a new stake in shares of Establishment Labs during the 3rd quarter worth approximately $1,731,000. Finally, Point72 Asset Management L.P. grew its position in shares of Establishment Labs by 210.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 49,400 shares of the company’s stock worth $2,138,000 after buying an additional 33,507 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.